المؤلفون: Kalinsky, Kevin^{Aff1, IDs10549024074129_cor1}, Spring, Laura, Yam, Clinton, Bhave, Manali Ajay, Ntalla, Ioanna, Lai, Catherine, Sjekloca, Nikoleta, Stwalley, Brian, Stokes, Michael, Taylor, Aliki, Nanda, Rita

المصدر: Breast Cancer Research and Treatment. :1-12

المؤلفون: Freeman, Jincong Q.^{Aff1, Aff2, Aff3}, Sheade, Jori B.^{Aff4, Aff5}, Zhao, Fangyuan, Olopade, Olufunmilayo I.^{Aff4, Aff6}, Huo, Dezheng^{Aff1, Aff6}, Nanda, Rita^{Aff4, Aff6, Aff7, IDs10549024073631_cor6}

المصدر: Breast Cancer Research and Treatment. :1-17

المؤلفون: Magbanua, Mark Jesus M, Brown Swigart, Lamorna, Ahmed, Ziad, Sayaman, Rosalyn W, Renner, Derrick, Kalashnikova, Ekaterina, Hirst, Gillian L, Yau, Christina, Wolf, Denise M, Li, Wen, Delson, Amy L, Asare, Smita, Liu, Minetta C, Albain, Kathy, Chien, A Jo, Forero-Torres, Andres, Isaacs, Claudine, Nanda, Rita, Tripathy, Debu, Rodriguez, Angel, Sethi, Himanshu, Aleshin, Alexey, Rabinowitz, Matthew, Perlmutter, Jane, Symmans, W Fraser, Yee, Douglas, Hylton, Nola M, Esserman, Laura J, DeMichele, Angela M, Rugo, Hope S, van 't Veer, Laura J

المصدر: Cancer Cell. 41(6)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Breast Cancer, Cancer, Genetics, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Humans, Female, Breast Neoplasms, Triple Negative Breast Neoplasms, Circulating Tumor DNA, Neoadjuvant Therapy, Clinical Relevance, Antineoplastic Combined Chemotherapy Protocols, Biology, Receptor, ErbB-2, Receptor, erbB-2, circulating tumor DNA, gene expression, neoadjuvant chemotherapy, pathologic complete response, receptor subtype, residual cancer burden, Neurosciences, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis

الوصف: Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment via non-invasive tumor burden assessment. To investigate subtype-specific differences in the clinical significance and biology of ctDNA shedding, we perform serial personalized ctDNA analysis in hormone receptor (HR)-positive/HER2-negative breast cancer and triple-negative breast cancer (TNBC) patients receiving neoadjuvant chemotherapy (NAC) in the I-SPY2 trial. ctDNA positivity rates before, during, and after NAC are higher in TNBC than in HR-positive/HER2-negative breast cancer patients. Early clearance of ctDNA 3 weeks after treatment initiation predicts a favorable response to NAC in TNBC only. Whereas ctDNA positivity associates with reduced distant recurrence-free survival in both subtypes. Conversely, ctDNA negativity after NAC correlates with improved outcomes, even in patients with extensive residual cancer. Pretreatment tumor mRNA profiling reveals associations between ctDNA shedding and cell cycle and immune-associated signaling. On the basis of these findings, the I-SPY2 trial will prospectively test ctDNA for utility in redirecting therapy to improve response and prognosis.

URL الوصول: https://escholarship.org/uc/item/6g68j14c

المؤلفون: Lang, Julie E, Forero-Torres, Andres, Yee, Douglas, Yau, Christina, Wolf, Denise, Park, John, Parker, Barbara A, Chien, A Jo, Wallace, Anne M, Murthy, Rashmi, Albain, Kathy S, Ellis, Erin D, Beckwith, Heather, Haley, Barbara B, Elias, Anthony D, Boughey, Judy C, Yung, Rachel L, Isaacs, Claudine, Clark, Amy S, Han, Hyo S, Nanda, Rita, Khan, Qamar J, Edmiston, Kristen K, Stringer-Reasor, Erica, Price, Elissa, Joe, Bonnie, Liu, Minetta C, Brown-Swigart, Lamorna, Petricoin, Emanuel F, Wulfkuhle, Julia D, Buxton, Meredith, Clennell, Julia L, Sanil, Ashish, Berry, Scott, Asare, Smita M, Wilson, Amy, Hirst, Gillian L, Singhrao, Ruby, Asare, Adam L, Matthews, Jeffrey B, Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S, Symmans, W Fraser, van 't Veer, Laura J, Hylton, Nola M, DeMichele, Angela M, Berry, Donald A, Esserman, Laura J

المصدر: NPJ breast cancer. 8(1)

مصطلحات موضوعية: Clinical Research, Clinical Trials and Supportive Activities, Prevention, Breast Cancer, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions

الوصف: HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in patients with high-risk early-stage breast cancer. I-SPY2 is a multicenter, phase II adaptively randomized neoadjuvant (NAC) clinical trial enrolling patients with stage II-III breast cancer with tumors 2.5 cm or larger on the basis of hormone receptors (HR), HER2 and Mammaprint status. Multiple novel investigational agents plus standard chemotherapy are evaluated in parallel for the primary endpoint of pathologic complete response (pCR). Patients with HER2-negative breast cancer were eligible for randomization to ganetespib from October 2014 to October 2015. Of 233 women included in the final analysis, 140 were randomized to the standard NAC control; 93 were randomized to receive 150 mg/m2 ganetespib every 3 weeks with weekly paclitaxel over 12 weeks, followed by AC. Arms were balanced for hormone receptor status (51-52% HR-positive). Ganetespib did not graduate in any of the biomarker signatures studied before reaching maximum enrollment. Final estimated pCR rates were 26% vs. 18% HER2-negative, 38% vs. 22% HR-negative/HER2-negative, and 15% vs. 14% HR-positive/HER2-negative for ganetespib vs control, respectively. The predicted probability of success in phase 3 testing was 47% HER2-negative, 72% HR-negative/HER2-negative, and 19% HR-positive/HER2-negative. Ganetespib added to standard therapy is unlikely to yield substantially higher pCR rates in HER2-negative breast cancer compared to standard NAC, and neither HSP90 pathway nor replicative stress expression markers predicted response. HSP90 inhibitors remain of limited clinical interest in breast cancer, potentially in other clinical settings such as HER2-positive disease or in combination with anti-PD1 neoadjuvant chemotherapy in triple negative breast cancer.Trial registration: www.clinicaltrials.gov/ct2/show/NCT01042379.

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/6gs8z1df

المؤلفون: Matossian, Margarite, Chen, Nan, Nanda, Rita^{Aff1, IDs12609023004924_cor3}

المصدر: Current Breast Cancer Reports. 15(3):266-278

المؤلفون: Terman, Elizabeth, Sheade, Jori, Zhao, Fangyuan, Howard, Frederick M., Jaskowiak, Nora, Tseng, Jennifer, Chen, Nan, Hahn, Olwen, Fleming, Gini, Huo, Dezheng, Nanda, Rita^{Aff2, IDs1054902306943x_cor11}

المصدر: Breast Cancer Research and Treatment. 200(1):75-83

المؤلفون: Howard, Frederick M., Dolezal, James, Kochanny, Sara, Khramtsova, Galina, Vickery, Jasmine, Srisuwananukorn, Andrew, Woodard, Anna^{Aff1, Aff4}, Chen, Nan, Nanda, Rita, Perou, Charles M., Olopade, Olufunmilayo I., Huo, Dezheng, Pearson, Alexander T.^{Aff1, IDs41523023005305_cor13}

المصدر: npj Breast Cancer. 9(1)

المؤلفون: Miyashita, Minoru, Bell, Joshua S. K., Wenric, Stephane, Karaesmen, Ezgi, Rhead, Brooke, Kase, Matthew, Kaneva, Kristiyana, De La Vega, Francisco M., Zheng, Yonglan, Yoshimatsu, Toshio F., Khramtsova, Galina, Liu, Fang, Zhao, Fangyuan, Howard, Frederick M., Nanda, Rita, Beaubier, Nike, White, Kevin P.^{Aff2, Aff3}, Huo, Dezheng, Olopade, Olufunmilayo I.^{Aff1, IDs13058023016272_cor19}

المصدر: Breast Cancer Research. 25(1)

المؤلفون: Freeman, Jincong Q., Shubeck, Sarah, Howard, Frederick M., Chen, Nan, Nanda, Rita, Huo, Dezheng^{Aff1, Aff3, IDs4152302300536z_cor6}

المصدر: npj Breast Cancer. 9(1)

المؤلفون: Michaels, Elena, Chen, Nan, Nanda, Rita

المصدر: In Clinical Breast Cancer June 2024 24(4):263-270